Back

Early initiation of PCSK9 inhibitor therapy versus placebo in patients with acute coronary syndrome: a systematic review and meta-analysis

28 August 2023 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Treatment of acute coronary syndromes in clinical practice Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Mr Gustavo B Justino

Federal University of Santa Catarina, Florianopolis (Brazil)

7 More presentations in this session

Presentation thumbnail
Effect of evolocumab on platelet function in patients with acute coronary syndromes. An analysis of the randomized, double-blind, placebo-controlled EVOPACS Trial
Doctor K. Koskinas (Bern, CH)
Abstract Slides Video
Presentation thumbnail
ARCANGELO: an observational, prospective study with acute coronary syndrome patients undergoing percutaneous coronary intervention who receive cangrelor transitioning to oral P2Y12 inhibitors
Doctor L. De Luca (Pavia, IT)
Abstract Slides
Presentation thumbnail
Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis
Doctor S. Al Said (Boston, US)
Abstract Slides Video
Presentation thumbnail
SGLT2 inhibitor for secondary prevention in acute myocardial infarction patients with diabetes mellitus
Professor D. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
The effect of sodium-glucose co-transporter-2 inhibitors following anterior ST-segment elevation myocardial infarction
Doctor G. Incesu (Istanbul, TR)
Abstract Slides

Access the full session

Session thumbnail
Treatment of acute coronary syndromes in clinical practice

The Event

Event poster

ESC Congress 2023

28 August 2023 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Strike early-strike strong lipid-lowering strategy with PCSK9i in ACS patients. Real-world evidence from AT-TARGET-IT registry.
thumbnail
Congress Presentation
Acute LDL-C reduction post acute coronary syndrome: strike early and strike strong: from evidence to clinical practice
thumbnail
Congress Presentation
Early initiation of PCSK9 inhibitors in acute STEMI: Interim results of safety and efficacy from the EARLY-STEMI trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources